Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Foundation Medicine to Participate in Cure-One N1 Registry

NEW YORK (GenomeWeb) – Cure-One announced today that it has secured the participation of Guardant Health and Foundation Medicine in its N1 Registry.

The registry aims to accomplish several goals, including helping patients to gain access to quality genomic testing; to gather data that can elucidate the genetic basis of malignancy in order to help physicians make decisions for their patients; to collect genomic data to elucidate the complexity, intricacy, and application of NGS testing; to help patients enroll in clinical trials; and to collect information on patients who have, or will, receive NGS testing, among other things.

Foundation Medicine and Guardant have been named as "cornerstone" laboratories for the registry, and will provide NGS testing for solid tumors and liquid biopsies for enrolling patients in N1, Cure-One said. Further terms of the agreements were not disclosed.

"Guardant Health is the world leader in liquid biopsies, and its participation with our N1 Registry is a testament to its commitment to advance the field of precision medicine, and to increase the availability of noninvasive comprehensive sequencing to advanced cancer patients," Cure-One Founder and CEO Dane Dickson said in a statement.

"Foundation Medicine has long provided the highest quality of testing, while spearheading efforts for transparency and data sharing. As the leading clinical genomic sequencing laboratory, we are ecstatic for this collaboration with Foundation Medicine, and ultimately what it means for advancing patient care," Dickson added.

"Our expectation is that data collaboration with Cure-One serves as an important exemplar in the oncology community for the benefits of public-private partnerships in the area of data exchange," Foundation Medicine CEO Troy Cox noted in the statement.

At the American Society of Clinical Oncology's annual meeting in Chicago during the weekend, Cure-One said it has partnered with ASCO to help enroll patients into the Targeted Agent and Profiling Utilization Registry (TAPUR) study through its registry. The partnership with ASCO would allow patients in the registry to be evaluated for potential enrollment into TAPUR. "The eventual goal would be to have some direct connection between the N1 Registry testing results to prescreen patients for TAPUR inclusion, but this is something that will be discussed in the future," Dickson said at the meeting.